NCT02272777View on ClinicalTrials.gov

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

July 17, 2014

Primary Completion Date

January 30, 2017

Study Completion Date

January 30, 2017

Conditions
Leukemia
Interventions
DRUG

Imatinib

Imatinib 400mg QD，300mg QD or 600mg QD

DRUG

Nilotinib

Nilotinib 300mg BID or 400mg QD

Trial Locations (12)

51000

Novartis Investigative Site, Guangzhou

100044

Novartis Investigative Site, Beijing

200025

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210008

Novartis Investigative Site, Nanjing

250012

Novartis Investigative Site, Jinan

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

350001

Novartis Investigative Site, Fuzhou

430022

Novartis Investigative Site, Wuhan

510515

Novartis Investigative Site, Guangzhou

610041

Novartis Investigative Site, Chengdu

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY